 The development of malaria vaccines that interrupt transmission, VIMD, could be crucial in eradicating the disease, with efforts primarily focused on plasmodium falciparum targeting morbidity and mortality. However, if VIMD is to be used as part of a repertoire for elimination or eradication, it will need to impact malaria transmission, including pre-erythrocytic and asexual stage vaccines that target the vector to disrupt parasite development in the mosquito. Additionally, targeting other malaria parasite species, especially plasmodium vivax, with novel therapeutic or preventive vaccines could have enormous impact. A TPP for VIMD is proposed along with a research agenda to address current knowledge gaps and develop necessary tools for design and development of VIMD. This article was authored by Maliura Consultative Group on Vaccines.